Literature Review of 178 Cases of Adverse Drug Reaction Induced by Oxycodone Hydrochloride

doi:10.19803/j.1672-8629.2021.01.14

Abstract

CLC Number:

R994.11

GAO Xiaohua. Literature Review of 178 Cases of Adverse Drug Reaction Induced by Oxycodone Hydrochloride[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 72-76.

[1] Yu HX,Zhao YB,He J.A case of interstitial pneumonia caused by oxycodone hydrochloride and a review of the literature[J].Journal of China Medical University(中国医科大学学报),2013,42(9):856-859.
[2] Chen T,Wu HY,Zhang CL,Domestic literature analysis of adverse reactions to oxycodone[J].Chinese Journal of Pharmacoepidemiology(药物流行病学杂志),2018,23(1):53-57.
[3] Zhu B.Efficacy and Side effects of oxycodone hydrochloride controlled-release tablets in the treatment of moderate to severe cancer pain[J].Journal of Practical Medical Technology(实用医技杂志),2013,32(6):68-69.
[4] Huang LL,Gao HF.Oxycodone hydrochloride sustained-release tablets in the treatment of cancer pain induced delirium:a case report[J].Modern pharmaceutical applications in China(中国现代药物应用),2019,13(8):154-155.
[5] Zhou L,Gao HF.Oxycodone hydrochloride sustained-release tablets in the treatment of cancer pain induced delirium:a case report[J].Basic and clinical of tumor(肿瘤基础与临床),2015,28(1):82-83.
[6] Zhang P,Gao SL,Hu ZT.Observation and nursing intervention of adverse reactions of oxycodone hydrochloride sustained-release tablets in treatment of cancer pain in patients with esophageal cancer[J].Anhui medicine(安徽医药),2015,19(12):192-193.
[7] Yu WJ,Liu J.Comparative analysis of the efficacy and adverse reactions of oxycodone hydrochloride sustained-release tablets and morphine sulfate sustained-release tablets in the treatment of severe cancer pain[J].Qingdao Medical Health(青岛医药卫生),2011,43(3):193-195.
[8] Ye YM,Xiao XX.Analysis of curative effect and side effect of oxycodone hydrochloride controlled release tablets and morphine sulfate sustained release tablets on 83 patients with severe cancer pain[J].Medical frontier(医药前沿),2012,2(8):69-70.
[9] Hu HM,Li MQ,Wu SN,et al.Analysis of curative effect and Adverse reaction of oxycodone hydrochloride sustained-release tablets combined with morphine release tablets in alleviating cancer pain[J].Journal of Practical Cancer(实用癌症杂志),2016,31(2):167-169.
[10] Chen QH.Nursing intervention on adverse reaction rate of oral oxycodone treatment of cancer pain[[J].Jilin medicine(吉林医学),2013,34(18):3722.
[11] Zang SW,Ding HJ,et al.Observation and nursing of adverse reactions of oxycodone hydrochloride controlled-release tablets in treatment of cancer pain[J].Chinese journal of practical nursing(中国实用护理杂志),2006,22(1):46.
[12] Sun Y,Ma LN,Wang LL.Effect of intravenous oxycodone hydrochloride pretreatment on relieving pain of propofol injection and postoperative adverse reactions at injection site.[J].Guangdong Medical Science(广东医学),2008,39(24):132-135.
[13] Li SY,Shang ZZ,Xue G.Effect of oxycodone hydrochloride controlled-release tablets on cancer pain relief[J].Shaanxi oncological medicine(陕西肿瘤医学),2002,10(1):16-18.
[14] Chai F,Pan HM,et al.Clinical observation of 72 cases of moderate and severe cancer pain treated with oxycodone controlled-release tablets[J].Chinese cancer clinic(中国肿瘤临床),2009,36(21):1213-1215.
[15] Chen ZH,Zhou SL.Clinical observation of oxycodone hydrochloride sustained-release tablets in the treatment of 60 cases of moderate and severe cancer pain[J].Modern oncology medicine(现代肿瘤医学),2014,22(11):2715-2717.
[16] Chen K,Cai H,Wei Y,et al.Retrospective analysis of oxycodone hydrochloride sustained-release tablets and morphine hydrochloride sustained-release tablets in the treatment of moderate cancer pain[J].Chinese pharmacists(中国药师),2014,17(7):1170-1172.
[17] Liu YH,Fan ZY,Jin YY,et al.Safety and efficacy of oxycodone hydrochloride injection in the recovery period of general anesthesia[J].Chinese journal of new drugs(中国新药杂志),2015,6(4):427-429.
[18] Li BX,Liu GL.Oxycodone hydrochloride controlled-release tablets for the treatment of moderate to severe cancer pain in 46 cases[J].Chinese journal of medical advanced studies(中国医师进修杂志),2010,33(25):68-70.
[19] Chen K,Xie H,Zhou J,et al.Efficacy evaluation of oxycodone hydrochloride sustained-release tablets in the treatment of moderate to severe cancer pain in 74 cases[J].China pharmaceutical industry(中国药业),2014,22(11):25-27.
[20] Yi Y,Jia LH,Zhang WL,et al.Dysuria caused by oral oxycodone hydrochloride sustained-release tablets in 1 case[J].Military medicine(军事医学),2015,21(3):240.
[21] Li XE.Central inhibition induced by routine dose of oxycodone hydrochloride controlled-release tablets:report of 1 case[J].Jiangxi pharmaceutical(江西医药),2009,44(11):52.
[22] Cai ZH,Zhang CY.Observation of therapeutic effect of acupoint application on oxycodone hydrochloride induced constipation[J].Hebei medicine(河北医药),2014,8(4):581-582.
[23] Huang ZZ,Wu HL,Ding QF,et al.Rescue and nursing care of respiratory depression induced by overdose oxycodone hydrochloride sustained release tablets taken by mistake in patients with severe cancer pain[J].Nursing and Rehabilitation(护理与康复),2008,17(1):106-108.
[24] Zuo YJ,Li YB.Analysis on the use of narcotic drugs in out-patient cancer patients in our hospital from2011 to 2012[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2013(7):38-39+42.
[25] Li X.Safety and efficacy of oxycodone hydrochloride injection in the recovery period of general anesthesia[J].Frontiers of medicine(医药前沿),2016,6(30):141-142.
[26] Li YL.The safe application of oxycodone sustained-release preparation[J].Gansu medicine(甘肃医药),2009,28(4):320.
[27] Hou PF,Lin XY,Chen Q.Clinical efficacy and safety of oxycodone hydrochloride controlled-release tablets in the treatment of advanced cancer pain[J].Chinese journal of hospital pharmacy(中国医院药学杂志),2015,35(4):329-332.
[28] Liu W,Luan R,Qu SD,et al.Comparison of specifications of codeine and oxycodone compound preparations at home and abroad[J].Chinese Journal of Pharmacovigilance(中国药物警戒),2011,8(10):603-605.
[29] Liu JY.Clinical observation of oxycodone hydrochloride controlled-release tablets in the treatment of moderate to severe cancer pain[J].China pharmaceutical guide(中国医药导刊),2012,15(4):86-87.
[30] Zhou XM.Research progress of oxycodone hydrochloride controlled-release tablets in treatment of cancer pain[J].Journal of guangxi medical university(广西医科大学学报),2009,26(5):813-816.
[31] Liu RK,Sun GK,M Y,et al.Epidemiological investigation of dependence of codeine,oxycodone and dextropropofol compound preparations[J].Chinese journal of drug dependence,2004,13(3):213-217.
[32] Ma JL,Pang LY,Zhou LX,et al.Analysis of the risk of paracetamol oxycodone dependence and abuse[J].Chinese Journal of Pharmacovigilance,2012,10(8):476-478.

Literature Review of 178 Cases of Adverse Drug Reaction Induced by Oxycodone Hydrochloride

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[14]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[15]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.